PT - JOURNAL ARTICLE AU - Benjamin M Jacobs AU - Alastair J Noyce AU - Christopher JD Hardy AU - Jason D Warren AU - Charles R Marshall TI - Estimating the causal effect of hearing loss on Alzheimer’s disease: a Mendelian randomisation study AID - 10.1101/2020.02.25.20017525 DP - 2020 Jan 01 TA - medRxiv PG - 2020.02.25.20017525 4099 - http://medrxiv.org/content/early/2020/02/26/2020.02.25.20017525.short 4100 - http://medrxiv.org/content/early/2020/02/26/2020.02.25.20017525.full AB - Background Hearing loss has been identified as one of the most important risk factors for Alzheimer’s disease (AD). However, the causality of this association has not been established.Methods We used publicly available GWAS summary statistics to construct instrumental variables for age-related hearing difficulty. We tested these genetic instruments for association with the outcome of AD using AD GWAS summary statistics in a two-sample Mendelian randomisation analysis. We used inverse-variance weighted meta-analysis to estimate the causal effect of hearing-related traits on AD, followed by secondary sensitivity analyses including a mixture of experts approach.Results There was no strong evidence for a causal relationship between genetically-determined hearing difficulty (ORFE-IVW 1.27, 95% CI 0.89 to 1.82, p=0.189) and AD risk. There was no evidence to suggest that unbalanced horizontal pleiotropy was biasing the result. Power calculations indicated our instruments were sufficiently powered to detect the magnitude of effect described in case-control and cohort settings.Conclusions Our results suggest that the size of the observed relationship between hearing loss and AD cannot be completely accounted for by a direct causal influence. Hearing loss may have more utility as a risk marker for AD than as a modifiable risk factor.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe QMUL Preventive Neurology Unit is funded by the Barts Charity: grant reference number MGU0364Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are publicly available for download.